Ardelyx Inc (ARDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ardelyx Inc (ARDX) has a cash flow conversion efficiency ratio of -0.217x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.24 Million) by net assets ($148.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ARDX equity to assets ratio to measure how much of total assets are equity-financed.
Ardelyx Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ardelyx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Ardelyx Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Ardelyx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ardelyx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Bide Science and Technology Co. Ltd.
SHG:605298
|
0.025x |
|
Hefei Metalforming Mach Tool
SHG:603011
|
-0.003x |
|
Carlsberg Brewery Malaysia Bhd
KLSE:2836
|
0.636x |
|
Shenzhen Clou Electronics Co Ltd
SHE:002121
|
0.146x |
|
Koh Young Technology Inc
KQ:098460
|
0.055x |
|
Clear Channel Outdoor Holdings Inc
NYSE:CCO
|
-0.001x |
|
Shenzhen hongfuhan Technology Co. Ltd.
SHE:301086
|
N/A |
|
361 Degrees International Limited
F:36L
|
0.000x |
Annual Cash Flow Conversion Efficiency for Ardelyx Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ardelyx Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Ardelyx Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $166.95 Million | $-42.48 Million | -0.254x | +1.59% |
| 2024-12-31 | $173.29 Million | $-44.81 Million | -0.259x | +51.92% |
| 2023-12-31 | $166.82 Million | $-89.72 Million | -0.538x | +24.50% |
| 2022-12-31 | $98.33 Million | $-70.04 Million | -0.712x | +61.42% |
| 2021-12-31 | $82.62 Million | $-152.55 Million | -1.846x | -185.95% |
| 2020-12-31 | $126.11 Million | $-81.44 Million | -0.646x | -57.59% |
| 2019-12-31 | $186.66 Million | $-76.48 Million | -0.410x | +32.47% |
| 2018-12-31 | $115.81 Million | $-70.27 Million | -0.607x | -29.67% |
| 2017-12-31 | $139.31 Million | $-65.19 Million | -0.468x | +2.32% |
| 2016-12-31 | $193.15 Million | $-92.53 Million | -0.479x | +27.38% |
| 2015-12-31 | $108.90 Million | $-71.84 Million | -0.660x | -398.80% |
| 2014-12-31 | $60.68 Million | $13.40 Million | 0.221x | +189.28% |
| 2013-12-31 | $-7.32 Million | $1.81 Million | -0.247x | +98.61% |
| 2012-12-31 | $-1.24 Million | $21.98 Million | -17.769x | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more